Passage BIO, Inc. (PASG): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Passage BIO, Inc. (PASG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 2026 Equity Incentive Plan On November 5, 2026, Passage Bio, Inc. (“ Passage Bio ”) held a Special Meeting of Stockholders

Event
ReportedStock split

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 6, 2026, 11:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 11:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PASG
Bearish
high confidence
Mentioned
$PASG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PASGBearishLow
01

Why it matters

The filing provides the first public details of the merger structure and compensation changes, which are material for shareholders and may affect valuation.

02

Market read

Primary disclosure of a merger and new equity plan for a micro‑cap biotech, likely causing short‑term share price pressure.

03

What to watch

Potential synergies from Remix's assets and the reverse split mechanics may stabilize the share price.

Relevance 6/10Novelty 7/10Timing: pre‑market today

Background

Passage Bio filed an 8‑K reporting shareholder approval of a new equity incentive plan tied to its merger with Remix Therapeutics and outlining share issuance and reverse split details.

Company-level read

Ticker impact

$PASGBearishHigh confidence
Context

SEC 8‑K filing discloses Passage Bio's approval of a new 2026 Equity Incentive Plan and details of the pending merger with Remix, including share issuance and reverse split.

Expected impact

likely downward pressure as the market prices in dilution and merger uncertainty

Evidence & confidence

Primary disclosure of a material merger and compensation restructuring; investors typically react negatively to dilution risk.

Market effects

Biotech M&A activity may prompt peers to reassess valuation multiples.

Limited to U.S. micro‑cap biotech segment.

Minimal; no broader macro impact.

Counterpoint

If the merger creates a stronger combined pipeline, the dilution could be offset by long‑term upside.

Key entities

  • Passage Bio, Inc.

    Biotech firm filing the 8‑K and pursuing a merger with Remix.

  • Remix Therapeutics, Inc.

    Target company in the merger; its equity plans will be assumed by Passage Bio.

Related articles

$PASGMed

Passage Bio Received Notice of Noncompliance

Passage Bio received a noncompliance notice from Nasdaq for failing to meet the $2.5M stockholders' equity requirement, reporting only $50,000. The company expects its pending merger with Remix Therapeutics to resolve the issue, with shares expected to trade under the symbol RMTX post-merger.

$ASTSMed

AST SpaceMobile Sinks 8% as New Offering Filing Revives Dilution Fears

AST SpaceMobile (ASTS) fell 8% after filing for a new securities sale, raising dilution concerns. The company's share count rose from 200M to 300M between late 2024 and Q3 2026. AT&T (T) and Vodafone (VOD), which have stakes in AST, are also affected. AST's free cash flow was negative $1.8B over the last four quarters, with analysts expecting negative free cash flow through 2028.